Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 215

1.

Time lag to benefit after screening for breast and colorectal cancer: meta-analysis of survival data from the United States, Sweden, United Kingdom, and Denmark.

Lee SJ, Boscardin WJ, Stijacic-Cenzer I, Conell-Price J, O'Brien S, Walter LC.

BMJ. 2013 Jan 8;346:e8441. doi: 10.1136/bmj.e8441.

2.

Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force.

Humphrey LL, Helfand M, Chan BK, Woolf SH.

Ann Intern Med. 2002 Sep 3;137(5 Part 1):347-60.

PMID:
12204020
3.

Time to benefit for colorectal cancer screening: survival meta-analysis of flexible sigmoidoscopy trials.

Tang V, Boscardin WJ, Stijacic-Cenzer I, Lee SJ.

BMJ. 2015 Apr 16;350:h1662. doi: 10.1136/bmj.h1662. Erratum in: BMJ. 2015;350:h2228.

4.

Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood.

Mandel JS, Church TR, Ederer F, Bond JH.

J Natl Cancer Inst. 1999 Mar 3;91(5):434-7.

PMID:
10070942
5.

Review in depth and meta-analysis of controlled trials on colorectal cancer screening by faecal occult blood test.

Heresbach D, Manfredi S, D'halluin PN, Bretagne JF, Branger B.

Eur J Gastroenterol Hepatol. 2006 Apr;18(4):427-33. Review.

PMID:
16538116
6.

Mammography screening: a new estimate of number needed to screen to prevent one breast cancer death.

Hendrick RE, Helvie MA.

AJR Am J Roentgenol. 2012 Mar;198(3):723-8. doi: 10.2214/AJR.11.7146.

PMID:
22358016
7.

Screening mammography for women aged 40 to 49 years at average risk for breast cancer: an evidence-based analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2007;7(1):1-32. Epub 2007 Jan 1.

8.

Effectiveness of Breast Cancer Screening: Systematic Review and Meta-analysis to Update the 2009 U.S. Preventive Services Task Force Recommendation.

Nelson HD, Fu R, Cantor A, Pappas M, Daeges M, Humphrey L.

Ann Intern Med. 2016 Feb 16;164(4):244-55. doi: 10.7326/M15-0969. Epub 2016 Jan 12. Review.

PMID:
26756588
9.

Overview of the epidemiology methods and applications: strengths and limitations of observational study designs.

Colditz GA.

Crit Rev Food Sci Nutr. 2010;50 Suppl 1:10-2. doi: 10.1080/10408398.2010.526838.

10.

The importance of age in screening for cancer.

Law MR, Morris JK, Wald NJ.

J Med Screen. 1999;6(1):16-20.

PMID:
10321365
11.

Screening for colorectal cancer using the faecal occult blood test, hemoccult.

Towler BP, Irwig L, Glasziou P, Weller D, Kewenter J.

Cochrane Database Syst Rev. 2000;(2):CD001216. Review. Update in: Cochrane Database Syst Rev. 2007;(1):CD001216.

PMID:
10796760
12.

Benefits and Harms of Breast Cancer Screening: A Systematic Review.

Myers ER, Moorman P, Gierisch JM, Havrilesky LJ, Grimm LJ, Ghate S, Davidson B, Mongtomery RC, Crowley MJ, McCrory DC, Kendrick A, Sanders GD.

JAMA. 2015 Oct 20;314(15):1615-34. doi: 10.1001/jama.2015.13183. Review. Erratum in: JAMA. 2016 Apr 5;315(13):1406.

PMID:
26501537
13.

Effectiveness and economic impact of screening for colorectal cancer by mass fecal occult blood testing.

Helm JF, Russo MW, Biddle AK, Simpson KN, Ransohoff DF, Sandler RS.

Am J Gastroenterol. 2000 Nov;95(11):3250-8.

PMID:
11095350
14.

Get screened: a pragmatic randomized controlled trial to increase mammography and colorectal cancer screening in a large, safety net practice.

Fiscella K, Yosha A, Hendren SK, Humiston S, Winters P, Ford P, Loader S, Specht R, Pope S, Adris A, Marcus S.

BMC Health Serv Res. 2010 Sep 23;10:280. doi: 10.1186/1472-6963-10-280.

15.

The benefits and harms of breast cancer screening: an independent review.

Independent UK Panel on Breast Cancer Screening.

Lancet. 2012 Nov 17;380(9855):1778-86. doi: 10.1016/S0140-6736(12)61611-0. Epub 2012 Oct 30. Review.

PMID:
23117178
16.

Estimates of costs and effects of screening for colorectal cancer in the United States.

Byers T, Gorsky R.

Cancer. 1992 Sep 1;70(5 Suppl):1288-95.

PMID:
1387342
17.

Cancer screening estimates for U.S. metropolitan areas.

Nelson DE, Bolen J, Marcus S, Wells HE, Meissner H.

Am J Prev Med. 2003 May;24(4):301-9.

PMID:
12726867
18.

Meta-analysis of breast cancer mortality benefit and overdiagnosis adjusted for adherence: improving information on the effects of attending screening mammography.

Jacklyn G, Glasziou P, Macaskill P, Barratt A.

Br J Cancer. 2016 May 24;114(11):1269-76. doi: 10.1038/bjc.2016.90. Epub 2016 Apr 28.

19.

United States Preventive Services Task Force screening mammography recommendations: science ignored.

Hendrick RE, Helvie MA.

AJR Am J Roentgenol. 2011 Feb;196(2):W112-6. doi: 10.2214/AJR.10.5609.

PMID:
21257850
20.

Breast and colorectal cancer screening and sources of cancer information among older women in the United States: results from the 2003 Health Information National Trends Survey.

Coughlin SS, Berkowitz Z, Hawkins NA, Tangka F.

Prev Chronic Dis. 2007 Jul;4(3):A57. Epub 2007 Jun 15. Erratum in: Prev Chronic Dis. 2007 Oct;4(4):A114.

Supplemental Content

Support Center